On June 26, Zai Lab fell 5.04% in regular trading, trading at approximately HK$13.8/share, with turnover of HK$97.96 million. The decline reflects continued fallout from partner Novocure's Phase 3 clinical trial failure combined with broad biotech sector weakness.

Novocure announced on June 18 that its Tumor Treating Fields (TTFields) therapy for glioblastoma failed to meet the overall survival primary endpoint in the Phase 3 TRIDENT trial, reporting HR of 0.953 and p-value of 0.519. Novocure plunged 20% on the announcement. Zai Lab holds Greater China commercial rights for TTFields, marketed domestically under the OPTUNE brand, and the negative pipeline valuation impact continues to be digested by the market.

Additionally, the company recently disclosed a Form 144 proposed securities sale filing, further pressuring market sentiment. Within the Biotechnology sector, AKESO fell 5.15%, INNOVENT BIO fell 2.17%, REMEGEN fell 2.36%, 3SBIO fell 0.87%, and BEIGENE fell 0.84%, indicating broad sector weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)